Adial Pharmaceuticals, Inc. announced on July 14, 2025 that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) by maintaining stockholders’ equity of at least $2,500,000. This step reinforces investor confidence and supports the company’s growth strategy. Adial Pharmaceuticals focuses on developing therapies for addiction and related disorders, with its lead drug product, AD04, showing promise in treating Alcohol Use Disorder. The company aims to create value for shareholders and potentially expand AD04’s applications to other addictive disorders like Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.

Read more at GlobeNewswire: Adial Pharmaceuticals Regains Compliance with Nasdaq